# MIMEDX Announces Launch of G4Derm® Plus
Canonical URL: https://biopharmsignal.com/news/MDXG/mimedx-announces-launch-of-g4dermr-plus
Ticker: MDXG
Company: MiMedx
Source: MiMedx
Published: 2026-05-08 12:00 EST
Original Source URL: https://mimedx.gcs-web.com
## Summary

Flowable Biomimetic Matrix Adds Self-Assembling Peptide Technology to Company’s Portfolio G4Derm Plus Added to Premier and Vizient GPO Agreements MARIETTA, Ga., May 08, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the commercial launch of

## Article Body
Flowable Biomimetic Matrix Adds Self-Assembling Peptide Technology to Company’s Portfolio G4Derm Plus Added to Premier and Vizient GPO Agreements MARIETTA, Ga., May 08, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the commercial launch of
## Recent Company News
- 2026-05-21 12:45 EST — [MIMEDX to Participate in Craig-Hallum 23rd Annual Institutional Investor Conference](https://biopharmsignal.com/news/MDXG/mimedx-to-participate-in-craig-hallum-23rd-annual-institutional-investor-conference) — Source: MiMedx
- 2026-05-08 12:00 EST — [MIMEDX Announces Launch of G4Derm® Plus](https://biopharmsignal.com/news/MDXG/mimedx-announces-launch-of-g4dermr-plus) — Source: MiMedx
- 2026-04-29 20:01 EST — [MIMEDX Announces First Quarter 2026 Operating & Financial Results](https://biopharmsignal.com/news/MDXG/mimedx-announces-first-quarter-2026-operating-and-financial-results) — Source: MiMedx
- 2026-04-22 12:00 EST — [MIMEDX to Host First Quarter 2026 Operating and Financial Results Conference Call on April 29](https://biopharmsignal.com/news/MDXG/mimedx-to-host-first-quarter-2026-operating-and-financial-results-conference-call-on-april-29) — Source: MiMedx
- 2026-04-16 12:00 EST — [MIMEDX Announces Restructuring and Cost Reduction Initiative](https://biopharmsignal.com/news/MDXG/mimedx-announces-restructuring-and-cost-reduction-initiative) — Source: MiMedx
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)